| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 56 | 2025 | 657 | 12.790 |
Why?
|
| Renal Insufficiency, Chronic | 49 | 2026 | 795 | 6.840 |
Why?
|
| Glomerular Filtration Rate | 38 | 2025 | 533 | 3.380 |
Why?
|
| Alberta | 55 | 2026 | 61 | 3.090 |
Why?
|
| Kidney Failure, Chronic | 20 | 2026 | 923 | 2.630 |
Why?
|
| Contrast Media | 9 | 2022 | 459 | 2.590 |
Why?
|
| Percutaneous Coronary Intervention | 9 | 2024 | 272 | 2.420 |
Why?
|
| Acute Coronary Syndrome | 8 | 2023 | 193 | 2.340 |
Why?
|
| Risk Assessment | 29 | 2023 | 3460 | 2.260 |
Why?
|
| Renal Replacement Therapy | 10 | 2026 | 157 | 2.030 |
Why?
|
| Coronary Angiography | 8 | 2022 | 442 | 2.030 |
Why?
|
| Renal Dialysis | 26 | 2024 | 928 | 2.020 |
Why?
|
| Kidney | 18 | 2024 | 1279 | 2.010 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2022 | 199 | 1.700 |
Why?
|
| Postoperative Complications | 11 | 2025 | 2967 | 1.600 |
Why?
|
| Creatinine | 18 | 2024 | 378 | 1.540 |
Why?
|
| Cardiac Catheterization | 7 | 2020 | 619 | 1.480 |
Why?
|
| Aged | 86 | 2026 | 19994 | 1.370 |
Why?
|
| Coronary Artery Disease | 10 | 2024 | 818 | 1.330 |
Why?
|
| Cohort Studies | 38 | 2026 | 4920 | 1.320 |
Why?
|
| Middle Aged | 91 | 2026 | 27321 | 1.300 |
Why?
|
| Surgical Procedures, Operative | 5 | 2021 | 225 | 1.270 |
Why?
|
| Cardiovascular Diseases | 16 | 2025 | 2022 | 1.200 |
Why?
|
| Humans | 164 | 2026 | 126057 | 1.190 |
Why?
|
| Male | 107 | 2026 | 62073 | 1.140 |
Why?
|
| Aged, 80 and over | 42 | 2026 | 6550 | 1.120 |
Why?
|
| Electronic Health Records | 4 | 2025 | 777 | 1.110 |
Why?
|
| Nephrology | 4 | 2022 | 153 | 1.110 |
Why?
|
| Risk Factors | 43 | 2024 | 10393 | 1.110 |
Why?
|
| Female | 110 | 2026 | 67899 | 1.100 |
Why?
|
| Hospitalization | 21 | 2020 | 1838 | 1.100 |
Why?
|
| Kidney Diseases | 9 | 2024 | 477 | 1.040 |
Why?
|
| Incidence | 24 | 2025 | 3213 | 0.970 |
Why?
|
| Renal Insufficiency | 7 | 2025 | 237 | 0.970 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1227 | 0.960 |
Why?
|
| Prognosis | 23 | 2023 | 4708 | 0.880 |
Why?
|
| Diabetes Mellitus | 8 | 2025 | 867 | 0.850 |
Why?
|
| Models, Biological | 3 | 2019 | 1371 | 0.840 |
Why?
|
| Cause of Death | 7 | 2020 | 473 | 0.820 |
Why?
|
| Quality of Life | 13 | 2025 | 2023 | 0.810 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 664 | 0.780 |
Why?
|
| Proteinuria | 6 | 2018 | 107 | 0.780 |
Why?
|
| Health Care Costs | 5 | 2022 | 383 | 0.780 |
Why?
|
| Nurse Practitioners | 1 | 2023 | 47 | 0.770 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2020 | 1124 | 0.760 |
Why?
|
| Albuminuria | 8 | 2020 | 103 | 0.760 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2025 | 202 | 0.760 |
Why?
|
| Medical Audit | 1 | 2022 | 96 | 0.740 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 293 | 0.720 |
Why?
|
| Disease Progression | 12 | 2022 | 2099 | 0.720 |
Why?
|
| Feedback | 1 | 2022 | 149 | 0.710 |
Why?
|
| Angina Pectoris | 4 | 2023 | 51 | 0.710 |
Why?
|
| Ileostomy | 1 | 2021 | 31 | 0.700 |
Why?
|
| Adult | 55 | 2026 | 30253 | 0.680 |
Why?
|
| Myocardial Infarction | 7 | 2022 | 908 | 0.680 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 729 | 0.670 |
Why?
|
| Arteriovenous Shunt, Surgical | 6 | 2017 | 92 | 0.670 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2016 | 88 | 0.660 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2016 | 62 | 0.660 |
Why?
|
| Retrospective Studies | 41 | 2025 | 16768 | 0.660 |
Why?
|
| Diuretics | 1 | 2021 | 140 | 0.650 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 287 | 0.650 |
Why?
|
| Hypoxia | 3 | 2016 | 243 | 0.640 |
Why?
|
| Self-Management | 4 | 2025 | 111 | 0.640 |
Why?
|
| Comorbidity | 11 | 2018 | 1537 | 0.610 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 84 | 0.600 |
Why?
|
| Quality Indicators, Health Care | 2 | 2025 | 220 | 0.600 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 203 | 0.590 |
Why?
|
| Coronary Artery Bypass | 4 | 2024 | 480 | 0.590 |
Why?
|
| Disease Management | 2 | 2020 | 533 | 0.590 |
Why?
|
| Kidney Transplantation | 3 | 2026 | 561 | 0.560 |
Why?
|
| Telemedicine | 4 | 2025 | 486 | 0.550 |
Why?
|
| Models, Theoretical | 3 | 2019 | 355 | 0.550 |
Why?
|
| Canada | 15 | 2024 | 314 | 0.550 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 277 | 0.550 |
Why?
|
| Aftercare | 2 | 2023 | 149 | 0.540 |
Why?
|
| Communication | 2 | 2020 | 513 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 742 | 0.520 |
Why?
|
| Acute Disease | 4 | 2024 | 1046 | 0.520 |
Why?
|
| Severity of Illness Index | 17 | 2025 | 2936 | 0.510 |
Why?
|
| Urination | 1 | 2016 | 27 | 0.510 |
Why?
|
| Intensive Care Units | 7 | 2025 | 490 | 0.510 |
Why?
|
| Epidural Abscess | 1 | 2016 | 11 | 0.510 |
Why?
|
| Peptide Fragments | 1 | 2020 | 745 | 0.490 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 196 | 0.480 |
Why?
|
| Kidney Function Tests | 8 | 2019 | 130 | 0.470 |
Why?
|
| Mortality | 5 | 2020 | 249 | 0.460 |
Why?
|
| Catheterization, Central Venous | 3 | 2017 | 141 | 0.460 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 317 | 0.460 |
Why?
|
| Mandibular Advancement | 1 | 2014 | 5 | 0.450 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 701 | 0.450 |
Why?
|
| Length of Stay | 6 | 2025 | 1324 | 0.440 |
Why?
|
| Qualitative Research | 7 | 2025 | 658 | 0.430 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2021 | 128 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2025 | 1174 | 0.420 |
Why?
|
| Polyuria | 1 | 2013 | 10 | 0.410 |
Why?
|
| Patient Admission | 4 | 2020 | 170 | 0.400 |
Why?
|
| Renal Artery Obstruction | 1 | 2013 | 39 | 0.400 |
Why?
|
| Time Factors | 18 | 2023 | 6007 | 0.390 |
Why?
|
| Obesity | 4 | 2019 | 2330 | 0.390 |
Why?
|
| Patient Participation | 3 | 2020 | 230 | 0.380 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 5050 | 0.380 |
Why?
|
| Critical Care | 2 | 2020 | 661 | 0.380 |
Why?
|
| Veterans Health | 1 | 2014 | 171 | 0.380 |
Why?
|
| Hyponatremia | 1 | 2013 | 73 | 0.380 |
Why?
|
| Hypertension | 3 | 2015 | 1288 | 0.370 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 693 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 199 | 0.350 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 220 | 0.350 |
Why?
|
| Treatment Outcome | 17 | 2024 | 12315 | 0.350 |
Why?
|
| Ischemic Attack, Transient | 3 | 2023 | 59 | 0.350 |
Why?
|
| Health Personnel | 5 | 2025 | 531 | 0.350 |
Why?
|
| Societies, Medical | 2 | 2018 | 725 | 0.320 |
Why?
|
| Patient Discharge | 4 | 2025 | 467 | 0.320 |
Why?
|
| Conservative Treatment | 2 | 2023 | 37 | 0.320 |
Why?
|
| Registries | 8 | 2025 | 1476 | 0.310 |
Why?
|
| Risk Adjustment | 2 | 2021 | 53 | 0.300 |
Why?
|
| Focus Groups | 4 | 2025 | 215 | 0.300 |
Why?
|
| Depression | 3 | 2024 | 1292 | 0.290 |
Why?
|
| Chronic Disease | 6 | 2023 | 1187 | 0.270 |
Why?
|
| Forecasting | 2 | 2021 | 350 | 0.270 |
Why?
|
| Peritoneal Dialysis | 2 | 2022 | 129 | 0.270 |
Why?
|
| Warfarin | 3 | 2023 | 112 | 0.270 |
Why?
|
| Coronary Disease | 3 | 2019 | 627 | 0.270 |
Why?
|
| Predictive Value of Tests | 8 | 2020 | 2180 | 0.260 |
Why?
|
| Heart Failure | 7 | 2017 | 2173 | 0.260 |
Why?
|
| Hypertension, Malignant | 2 | 2017 | 7 | 0.260 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 120 | 0.260 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 150 | 0.260 |
Why?
|
| Hospitals | 4 | 2024 | 417 | 0.260 |
Why?
|
| Sick Leave | 2 | 2023 | 5 | 0.250 |
Why?
|
| Odds Ratio | 4 | 2021 | 1188 | 0.250 |
Why?
|
| Databases, Factual | 7 | 2020 | 1175 | 0.250 |
Why?
|
| Recovery of Function | 4 | 2023 | 428 | 0.250 |
Why?
|
| Epidemiologic Research Design | 2 | 2016 | 6 | 0.240 |
Why?
|
| Health Resources | 2 | 2017 | 126 | 0.240 |
Why?
|
| Fibrosis | 2 | 2018 | 396 | 0.240 |
Why?
|
| Hyperkalemia | 2 | 2017 | 61 | 0.240 |
Why?
|
| Decision Making | 3 | 2022 | 667 | 0.230 |
Why?
|
| Internet | 2 | 2025 | 400 | 0.230 |
Why?
|
| Hospital Mortality | 5 | 2020 | 976 | 0.230 |
Why?
|
| Quality Improvement | 3 | 2021 | 677 | 0.230 |
Why?
|
| Perioperative Care | 3 | 2022 | 210 | 0.220 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 1350 | 0.220 |
Why?
|
| Survival Analysis | 3 | 2020 | 1476 | 0.220 |
Why?
|
| Patient Preference | 2 | 2023 | 142 | 0.220 |
Why?
|
| Critical Illness | 3 | 2025 | 603 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2025 | 108 | 0.210 |
Why?
|
| Age Factors | 6 | 2025 | 2771 | 0.210 |
Why?
|
| Anticoagulants | 3 | 2023 | 563 | 0.210 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3303 | 0.210 |
Why?
|
| Bacteremia | 1 | 2008 | 420 | 0.210 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 3905 | 0.210 |
Why?
|
| Nephrologists | 1 | 2023 | 14 | 0.210 |
Why?
|
| Stroke | 3 | 2023 | 1005 | 0.200 |
Why?
|
| Global Health | 3 | 2018 | 605 | 0.200 |
Why?
|
| Vascular Access Devices | 2 | 2013 | 35 | 0.200 |
Why?
|
| Insulins | 1 | 2022 | 19 | 0.190 |
Why?
|
| Multimorbidity | 1 | 2022 | 25 | 0.190 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2023 | 64 | 0.180 |
Why?
|
| Hemorrhage | 4 | 2023 | 472 | 0.180 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 29 | 0.180 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2022 | 57 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 280 | 0.180 |
Why?
|
| Patient Readmission | 1 | 2025 | 388 | 0.180 |
Why?
|
| Hypoglycemia | 1 | 2022 | 177 | 0.170 |
Why?
|
| Risk | 4 | 2019 | 726 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2023 | 253 | 0.170 |
Why?
|
| Angina, Stable | 1 | 2020 | 7 | 0.170 |
Why?
|
| Physician-Patient Relations | 2 | 2024 | 430 | 0.170 |
Why?
|
| Image Enhancement | 2 | 2021 | 158 | 0.170 |
Why?
|
| Nitrogen Dioxide | 1 | 2020 | 16 | 0.170 |
Why?
|
| Polysomnography | 3 | 2016 | 147 | 0.170 |
Why?
|
| Health Status | 3 | 2018 | 379 | 0.170 |
Why?
|
| Population Dynamics | 1 | 2020 | 30 | 0.170 |
Why?
|
| Software | 1 | 2025 | 710 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 2868 | 0.160 |
Why?
|
| Patient Safety | 3 | 2021 | 434 | 0.160 |
Why?
|
| Propensity Score | 3 | 2020 | 238 | 0.160 |
Why?
|
| Psychometrics | 4 | 2025 | 655 | 0.160 |
Why?
|
| Air Pollution | 1 | 2020 | 72 | 0.160 |
Why?
|
| Young Adult | 8 | 2024 | 9617 | 0.160 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 52 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2019 | 66 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 2 | 2016 | 72 | 0.150 |
Why?
|
| Social Support | 2 | 2019 | 371 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 95 | 0.150 |
Why?
|
| Sepsis | 1 | 2023 | 490 | 0.150 |
Why?
|
| Patient Selection | 2 | 2014 | 702 | 0.150 |
Why?
|
| Interviews as Topic | 1 | 2020 | 422 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2020 | 82 | 0.150 |
Why?
|
| Algorithms | 2 | 2023 | 1615 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 222 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2020 | 172 | 0.150 |
Why?
|
| Dipeptidases | 1 | 2018 | 15 | 0.140 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 13 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2020 | 211 | 0.140 |
Why?
|
| Curcumin | 1 | 2018 | 43 | 0.140 |
Why?
|
| Estradiol | 1 | 2020 | 476 | 0.140 |
Why?
|
| Myocardial Revascularization | 1 | 2018 | 94 | 0.140 |
Why?
|
| Survival Rate | 6 | 2020 | 2060 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 424 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 223 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 171 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 264 | 0.140 |
Why?
|
| Colonoscopy | 1 | 2020 | 244 | 0.140 |
Why?
|
| Hepatectomy | 1 | 2018 | 119 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 168 | 0.140 |
Why?
|
| Gadolinium | 1 | 2018 | 110 | 0.130 |
Why?
|
| Medicine | 1 | 2018 | 100 | 0.130 |
Why?
|
| Elective Surgical Procedures | 2 | 2018 | 144 | 0.130 |
Why?
|
| Health Services, Indigenous | 1 | 2017 | 4 | 0.130 |
Why?
|
| Dementia | 1 | 2022 | 413 | 0.130 |
Why?
|
| Survivors | 2 | 2023 | 346 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 48 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2023 | 771 | 0.130 |
Why?
|
| Rural Health Services | 1 | 2017 | 27 | 0.130 |
Why?
|
| Epilepsy | 1 | 2024 | 843 | 0.130 |
Why?
|
| Pyrenes | 1 | 2016 | 5 | 0.130 |
Why?
|
| Postmenopause | 1 | 2017 | 140 | 0.130 |
Why?
|
| Indians, North American | 1 | 2017 | 72 | 0.130 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2016 | 4 | 0.120 |
Why?
|
| Health Promotion | 1 | 2020 | 400 | 0.120 |
Why?
|
| Mass Screening | 2 | 2024 | 805 | 0.120 |
Why?
|
| Prospective Studies | 6 | 2020 | 6090 | 0.120 |
Why?
|
| Catheterization | 1 | 2017 | 233 | 0.120 |
Why?
|
| Aortic Valve | 1 | 2019 | 411 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 29 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 294 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 71 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 535 | 0.120 |
Why?
|
| Catheter-Related Infections | 2 | 2017 | 136 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2016 | 331 | 0.120 |
Why?
|
| National Health Programs | 1 | 2015 | 20 | 0.120 |
Why?
|
| Lymphoma | 1 | 2018 | 319 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2016 | 73 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 175 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 224 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2018 | 256 | 0.110 |
Why?
|
| Thrombosis | 2 | 2017 | 500 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2015 | 82 | 0.110 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 336 | 0.110 |
Why?
|
| Consensus | 3 | 2022 | 544 | 0.100 |
Why?
|
| Caregivers | 1 | 2019 | 553 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2017 | 548 | 0.100 |
Why?
|
| Publication Bias | 1 | 2013 | 15 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2015 | 283 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1025 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2016 | 458 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2015 | 395 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 452 | 0.100 |
Why?
|
| Cardiology | 1 | 2018 | 474 | 0.100 |
Why?
|
| United States | 4 | 2018 | 11200 | 0.090 |
Why?
|
| Oxygen | 1 | 2015 | 540 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 749 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 216 | 0.090 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 64 | 0.090 |
Why?
|
| Ambulatory Care | 3 | 2023 | 392 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2013 | 187 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2010 | 48 | 0.090 |
Why?
|
| Creatine | 1 | 2010 | 39 | 0.080 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 620 | 0.080 |
Why?
|
| Biomarkers | 5 | 2019 | 3138 | 0.080 |
Why?
|
| Information Services | 1 | 2009 | 20 | 0.080 |
Why?
|
| Adolescent | 4 | 2021 | 19936 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 968 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 603 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3680 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 70 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 181 | 0.080 |
Why?
|
| Ontario | 2 | 2023 | 81 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 299 | 0.080 |
Why?
|
| ROC Curve | 2 | 2022 | 572 | 0.070 |
Why?
|
| Research Design | 2 | 2025 | 687 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2008 | 110 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1350 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1845 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 57 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 42 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2020 | 757 | 0.060 |
Why?
|
| Urinalysis | 2 | 2020 | 66 | 0.060 |
Why?
|
| Anemia | 1 | 2009 | 336 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 381 | 0.060 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 224 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2024 | 1 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2025 | 155 | 0.060 |
Why?
|
| Prevalence | 3 | 2017 | 2578 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2025 | 320 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 529 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 650 | 0.050 |
Why?
|
| United Kingdom | 2 | 2014 | 237 | 0.050 |
Why?
|
| Hypovolemia | 1 | 2022 | 7 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2025 | 464 | 0.050 |
Why?
|
| Logistic Models | 2 | 2020 | 1744 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 102 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 127 | 0.050 |
Why?
|
| Sex Factors | 1 | 2026 | 1294 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2022 | 98 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2016 | 308 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 238 | 0.040 |
Why?
|
| Inventions | 1 | 2021 | 19 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2022 | 198 | 0.040 |
Why?
|
| Exercise Test | 1 | 2022 | 239 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2019 | 1649 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 1421 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 20 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2021 | 69 | 0.040 |
Why?
|
| Health Planning | 1 | 2020 | 16 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 23 | 0.040 |
Why?
|
| Erythrocyte Indices | 1 | 2020 | 12 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 85 | 0.040 |
Why?
|
| Chlorides | 1 | 2020 | 98 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 220 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 130 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 232 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 246 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 50 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 88 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 68 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 324 | 0.040 |
Why?
|
| Potassium | 1 | 2020 | 260 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 295 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 274 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 130 | 0.040 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2018 | 15 | 0.040 |
Why?
|
| Pacemaker, Artificial | 1 | 2021 | 184 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2019 | 56 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 209 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 43 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 556 | 0.040 |
Why?
|
| Phagocytes | 1 | 2018 | 24 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 65 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1087 | 0.040 |
Why?
|
| Egypt | 1 | 2017 | 27 | 0.030 |
Why?
|
| Radiologists | 1 | 2018 | 49 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2018 | 103 | 0.030 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 14 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1593 | 0.030 |
Why?
|
| Catheter Obstruction | 1 | 2017 | 4 | 0.030 |
Why?
|
| Australasia | 1 | 2017 | 5 | 0.030 |
Why?
|
| Manitoba | 1 | 2017 | 3 | 0.030 |
Why?
|
| Aviation | 1 | 2017 | 5 | 0.030 |
Why?
|
| Motor Vehicles | 1 | 2017 | 7 | 0.030 |
Why?
|
| Perception | 1 | 2019 | 227 | 0.030 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 52 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 124 | 0.030 |
Why?
|
| Leukocytes | 1 | 2018 | 203 | 0.030 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 28 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 56 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 76 | 0.030 |
Why?
|
| Affect | 1 | 2018 | 167 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 94 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 165 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2018 | 147 | 0.030 |
Why?
|
| North America | 1 | 2017 | 250 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 123 | 0.030 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2016 | 10 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 666 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 179 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 353 | 0.030 |
Why?
|
| Palliative Care | 1 | 2020 | 438 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 31 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 440 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 331 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2016 | 176 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2019 | 460 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 356 | 0.030 |
Why?
|
| Emergencies | 1 | 2016 | 177 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 176 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1574 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 207 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 90 | 0.030 |
Why?
|
| Arteries | 1 | 2015 | 198 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 605 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 94 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 788 | 0.030 |
Why?
|
| Premedication | 1 | 2014 | 37 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 664 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 33105 | 0.030 |
Why?
|
| Wrist Injuries | 1 | 2013 | 7 | 0.030 |
Why?
|
| British Columbia | 1 | 2013 | 8 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 40 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 211 | 0.020 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 37 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2013 | 44 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 75 | 0.020 |
Why?
|
| Cognition | 1 | 2018 | 783 | 0.020 |
Why?
|
| Simvastatin | 1 | 2013 | 76 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 255 | 0.020 |
Why?
|
| Hip Fractures | 1 | 2013 | 67 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 399 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1216 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 486 | 0.020 |
Why?
|
| Physicians | 1 | 2018 | 618 | 0.020 |
Why?
|
| Reagent Strips | 1 | 2011 | 11 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 182 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 727 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 277 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 118 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 144 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 231 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 3704 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 152 | 0.020 |
Why?
|
| Heart Rate | 1 | 2013 | 565 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2027 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 403 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2014 | 381 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 254 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 4489 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 826 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 145 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 615 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1399 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4406 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2015 | 858 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 299 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3649 | 0.020 |
Why?
|
| Child | 1 | 2022 | 25061 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 17574 | 0.010 |
Why?
|